Unraveling the Proteome
for the Next Era of Precision Medicine
- Bertis' core
- Pan-omics Analysis solutions optimized
for academia and pharma research
- The world’s first commercialized
proteomics-based early diagnostic solution
for breast cancer
- Bertis to Present 10 Research Outcomes at HUPO 2023, Including Development of Next-generation Analysis Method for Proteomic Data
- Bertis to Present 10 Research Outcomes at HUPO 2023,Including Development of Next-generation Analysis Methodfor Proteomic Data- HUPO, one of the world's largest proteomics societies, is returning to Korea for the first time in 16 years to be held at BEXCO, Busan from September 17 to 21- Bertis joins as a major sponsor in the event which attracts over 1,000 scholars and key industry officials from 40 countries- Bertis presents 10 studies, including the development of next-generation mass spectrometry and single-cell proteomic analysis, and highlights its core technology framework, ‘ProteoID’, as well as nine essential technologiesBertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced on September 7 that it would participate in ‘2023 HUPO, Human Proteome Organization’, one of the largest international academic gatherings in the field of proteomics. The event will take place from September 17 to 21 in Busan, Korea.HUPO 2023, themed 'Together Through Proteomics,' is scheduled to be held at BEXCO in Busan. The event is expected to draw over 1,000 researchers and prominent figures from more than 40 countries. This annual event, inaugurated in France in 2002, has been held continuously, rotating through the Americas, Asia, Oceania, Europe, and Africa. It now returns to Korea after 16 years since its last appearance in Seoul in 2007During the event, Bertis will deliver presentations on 10 studies, including the development of next-generation mass spectrometry and single-cell proteomic analysis methodologies. The three main topics Bertis will cover in oral presentations are ▲ Broad Target Scanning (BTS) - a pragmatic LC-MS acquisition method for collecting population-scale real-world proteomics data ▲ Identification of Secreted Unannotated Small ORF Microproteins from Adipocytes and in Plasma to Elucidate Function of Novel Gene Product Proteins ▲ Spatial proteomic approaches for triple-negative breast cancer on single-cell resolution. In addition, the company will provide seven poster presentations on DeepMRM: Deep learning-based object detection model for proteomics data, Exploring the Human Aging Blood Proteome, and others. <Image> List of Bertis’ oral presentations to be delivered at HUPO 2023(See the overview of presentation details below)Seung-man Han, CEO of Bertis, said, “It is encouraging for the Korean proteomics industry and academia that the representative academic event in the proteomics field is held in Korea at this critical juncture when the use cases of proteomics technology are rapidly increasing across all areas of the bio industry. Bertis will also leverage the upcoming HUPO 2023 as an opportunity to introduce Korea's technologies to the global proteomics community and make its utmost efforts to contribute to substantial breakthroughs in the development of proteomics technology.Bertis plans to focus on promoting protein data analysis and interpretation capabilities, as well as know-how in technological commercialization through HUPO 2023. The company will set up a large promotional booth inside the conference hall to introduce nine core technologies related to biomarker discovery and algorithm development, diagnostic service commercialization, and advanced technology. The primary focus will be on the core technology framework ‘ProteoID(Proteome Integrated Determination)’. Furthermore, it will publicize its pipeline of multi-marker solutions for early diagnosis, including ‘MASTOCHECK®’, an early diagnosis blood test for breast cancer, and PASS (Pan-omics Analysis Service & Solution). <Image> ProteoID, Bertis’ core technology system, and nine essential technologiesThe name ProteoID is derived from the term 'proteoid roots,' which refers to the densely packed roots of plants. It implies the interactions among proteins, combinations of various disease markers, and the organic blend of proteomics technologies. Bertis is fully committed to realizing the potential of proteomics in clinical and medical contexts based on ProteoID, a technology system that encompasses all stages of utilizing proteomics technology, from protein data analysis to product and service commercialization.
- Bertis Initiates Commercialization of Diagnostic Solutions in the Middle East through MOU
- Bertis Initiates Commercialization of Diagnostic Solutionsin the Middle Eastthrough MOUwith Saudi Arabia's Largest Diagnostic Network- Expects support for joint R&D, licensing, and commercialization through cooperation with Al Borg Diagnostics and SaudiVax<Image>(From left) Logos of Al Borg Diagnostics, Bertis, SaudiVaxBertis (Co-CEOs Dong-Young Noh and Seung-Man Han), a proteomics-based precision medicine company announced the launch of PASS (Pan-omics Analysis Service) service in the United States through its wholly owned US subsidiary, Bertis Bioscience Inc.Pan-omics is the integration of complex “omics” datasets generated from the subfields of genomics, transcriptomics, proteomics and metabolomics to increase the understanding of pathophysiology, diagnosis and treatment of diseases. PASS is an insightful analysis solution leveraging Bertis’ pan-omics knowledge and know-how coupled with its proprietary bioinformatics and AI technology to deliver analytical services including the core protein identification and biomarker discovery but also drug development and clinical research processes.On August 7, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it had signed a memorandum of understanding (MOU) with Al Borg Diagnostics, a Saudi Arabian diagnostic company, and SaudiVax Inc., a biotechnology company, for entry to Saudi Arabia with its diagnosis solution.Under the MOU, Bertis, Al Borg Diagnostics, and SaudiVax will cooperate to commercialize a blood-based cancer diagnosis technology developed by Bertis in Saudi Arabia and neighboring countries. The MOU calls for Al Borg Diagnostics to transfer technological expertise and support joint R&D for the commercialization of Bertis’ diagnostic technology and execution of diagnostic testing by region, and SaudiVax to cooperate on data analysis, regulatory affairs, and joint R&D for the diagnostic test.Al Borg Diagnostics, established in 1998, is the largest network of private diagnostic laboratories in the GCC (Gulf Cooperation Council). It provides healthcare services to over 5,000 hospitals and clinics and with approximately 15,000 visitors daily. SaudiVax is a joint venture of a Saudi Arabian Family Holding company UYC, and U.S.-based PnuVax, which supplies biologics to the GCC and OIC (Organization of Islamic Countries).“As an organization responsible for the health promotion of local residents, we are pleased to have this opportunity to introduce the latest diagnostic technology,” said Al Borg Diagnostics Managing Director Dr. Mohammed Amin. “We will do our best to ensure that Bertis’ state-of-the-art diagnostic technology is utilized where it is needed and contributes to promoting the health of local people based on our network of diagnostic laboratories and diagnostic testing expertise.”“We are excited to be working with Bertis as they are leading the development of proteomics technology, which is emerging as the cutting-edge technology in the biomedical sciences.” Said SaudiVax Managing Director Prof. Mazen M. Hassanain. “We will closely cooperate with Bertis to help swiftly introduction of its state-of-the-art technologies including the blood-based cancer diagnosis solution, to the Middle East and contribute to biotechnology development in the region.”“As the proteomics-based diagnostic solution is a breakthrough technology that can enable early diagnosis of key diseases, we were able to take this opportunity to cooperate with influential partners in the region including the largest network of diagnostic laboratories,” said Bertis CEO Seung-man Han. “We will make utmost efforts and look forward to bringing the proteomics technologies developed by Bertis to healthcare providers and patients in the Middle East and Africa.”Bertis commercialized MASTOCHECK®, a proteomics-based breast cancer early diagnosis blood test, for the first time in the world. As of July 2023, MASTOCHECK® is available in more than 392 hospitals and medical check-up centers in Korea. In addition, over 40 medical institutes including Raffles Medical Group, the largest private medical group in Singapore, and Solis Breast Care & Surgery Centre provide examination services using MASTOCHECK®. As a follow-up pipeline, Bertis is developing early diagnosis solutions for pancreatic cancer and ovarian cancer.
- Bertis Pan-omics Analysis Solution and Systems (PASS) launched in the U.S.
- Bertis Pan-omics Analysis Solution and Systems (PASS) launched in the U.S.- Bertis, Inc.’s wholly owned US subsidiary, Bertis Bioscience, signed its first service agreement with the world-renowned Salk Institute for Biological Studies, to provide a PASS service using its CLIA lab and proteomics experts in San Diego, California.- In Korea, Bertis, Inc., already launched PASS in May 2022, offering a robust suite of analytical services including protein identifications, biomarker discovery and drug target discovery analytical services.Bertis (Co-CEOs Dong-Young Noh and Seung-Man Han), a proteomics-based precision medicine company announced the launch of PASS (Pan-omics Analysis Service) service in the United States through its wholly owned US subsidiary, Bertis Bioscience Inc.Pan-omics is the integration of complex “omics” datasets generated from the subfields of genomics, transcriptomics, proteomics and metabolomics to increase the understanding of pathophysiology, diagnosis and treatment of diseases. PASS is an insightful analysis solution leveraging Bertis’ pan-omics knowledge and know-how coupled with its proprietary bioinformatics and AI technology to deliver analytical services including the core protein identification and biomarker discovery but also drug development and clinical research processes.<Image> PASS LogoIn the US, Bertis’ wholly owned US subsidiary, Bertis Bioscience, has launched the much-anticipated PASS services after more than a year of preparation to assemble industry recognized experts in both mass spec-based proteomics as well as bioinformatics. The US PASS services will be provided at its CLIA Lab in San Diego. As part of the US PASS offerings, Bertis Bioscience will initially offer proof-of-principle studies for protein biomarker discovery using Seer’s proteograph and nanoparticle kits.On June 8, 2023, Bertis Biosciences signed its first proteomics-based analysis service agreement in the United States with the Salk Institute for Biological Studies, a San Diego-based non-profit life science research center. The Salk Institute is known for life-changing discoveries in the fields of cancer, neuroscience, aging, immunobiology, and plant biology. Six Nobel Prize winners conducted research at Salk, one of the world's leading research centers. Under this agreement, Bertis Bioscience will provide proteomic data analysis to look for novel human disease biomarkers.Han Seung-man, CEO of Bertis, said, "We are pleased with the market’s enthusiastic reception of our PASS service launched just last year. We attribute the success to the market’s recognition of Bertis’ proprietary technology and know-how in proteomics analysis and commercialization. Our technology and services have shown strong global competitiveness and receive favorable reception at various international conferences. We believe the US will provide a stage for us to showcase our expertise globally and build our PASS business by serving world-class research institutions as a start.”Amid the increasing demand for multiomics analysis data, PASS has received significant attention from industries such as biotech, pharmaceutical companies, and research institutes since its launch in Korea in May 2022. Leveraging its state-of-the-art analysis system and industry leading proteomics expertise, as of June, Bertis Inc. signed agreements for PASS with twenty companies, including national institutions, government-funded research institutes, and private companies.
- Bertis Publishes Findings on ‘DeepMRM’, a Targeted Proteomics Data Interpretation Software Package
- Bertis Publishes Findings on ‘DeepMRM’, a Targeted ProteomicsData Interpretation Software Package in International Journal-Publish findings on assessing the performance and accuracy of the self-developed ‘DeepMRM’ in ‘Cell Reports Methods’, an international journal, on July 12-According to the results of the comparative test on the performance of discovering protein candidates, DeepMRM has higher accuracy than existing software and has the lowest error percentage-Promote high-speed analysis in the clinical environment and improve reproducibility and scalability of targeted proteomics analysisOn July 12, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it had presented its findings on assessing the performance of ‘DeepMRM’, a software package based on deep learning algorithms for object detection, in ‘Cell Reports Methods’.‘DeepMRM’ is a software package which the Bertis research team has developed by employing deep learning technology with the aim of more efficiently and accurately conducting MRM (Multiple Reaction Monitoring), a representative analysis method for discovering targeted protein candidates. With an existing community standard tool for MRM, researchers often devote substantial time to manual data interpretation, which hinders the transferability, reproducibility, and scalability of this approach. Deep MRM addresses these limitations by utilizing deep learning technology for object detection.The Bertis Machine Learning team and its U.S. subsidiary Bertis Bioscience team utilized public MRM dataset to test the performance of DeepMRM against the most widely used Skyline. The results demonstrated that DeepMRM outperformed Skyline in both correlation coefficient between quantification values and actual values of analyzed proteomes, and MAAPE (Mean Arctangent Absolute Percentage Error), which measures average error values. Even when applying the mProphet algorithm, a filter that allows skyline to make the results more refined, DeepMRM's results were more accurate.><Image: Table comparing the performances of DeepMRM and existing software>With its superior performance, DeepMRM not only reduces proteomic analysis time in clinical research, but also improves the reproducibility of analysis results, increasing the reliability of results. In addition, thanks to its high scalability, DeepMRM can analyze other types of proteins, such as PRM (ParallelReaction Monitoring) and DIA (Data-Independent Acquisition) data, in addition to MRM data.<Image: Process for analyzing targeted proteomics using DeepMRM>Jungkap Park, Director of Machine Learning team at Bertis, said, “DeepMRM is an innovative analysis tool that can dramatically increase data throughput in Bertis' major research areas - multi-biomarker diagnostic solutions and analysis services. Bertis will continue its R&D efforts towards AI-powered analytical tools to develop a unique platform which enables the diagnosis and treatment of diseases and the discovery of targeted candidates for new drugs in the future.”Seung-man Han, CEO of Bertis, said, “In our attempts to overcome the limits of proteomics data interpretation by integrating bioinformatics and AI technologies with proteomics technology, the publication of a paper on DeepMRM holds great significance. As a leader in proteomics in Asia, Bertis will spare no efforts in developing innovative technologies that can fully unlock the potential of proteomics in R&D and actual clinical applications.”Bertis is devoting itself to a project to eliminate limitations on interpreting and using proteomics data by incorporating proteomics technology accumulated over 10 years with bioinformatics and AI technologies. In particular, the company is making R&D efforts for the SAN (Spectrum is All you Need) model with a view to developing an innovative health information interpretation model which can produce health information from proteomic biometric information by automating the information processing and interpretation process.
- Bertis Publishes Findings on 9 Protein Biomarkers and Algorithm-based Test Model
- Bertis Publishes Findings on 9 Protein Biomarkers andAlgorithm-based Test Model for Breast Cancer Early Detectionin International Journal- Propose a test model with AUC 0.9105 using 9 proteins as multiple biomarkers for breast cancer in stages 0-2- Develop an innovative platform for discovering and validating disease biomarkers based on its self-constructed quantifiable peptide libraryOn June 21st, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), presented its findings on developing a nine types of protein biomarkers blood test for early diagnosis of breast cancer using its library for quantitative analysis of proteins and artificial intelligence (AI) technology.Through this research, designed to develop an advanced blood test for breast cancer diagnosis, the Bertis research team combined the quantitative values of 9 protein biomarkers to present a diagnostic test model with an average AUC 0.9105 for stages 0-2 breast cancer, which is an improvement from that of ‘MASTOCHECK®,’ the world’s first proteomics-based blood test for early diagnosis of breast cancer developed and commercialized by Bertis.The research also revealed a platform for discovering and validating biomarkers that can drastically reduce time and cost in developing the proteomics-based diagnostic test. It uses 'PepQuant libraryTM', a library for quantifiable protein analysis developed by Bertis, which enables the discovery of biomarkers in the setting of a validation process. Instead of the existing difficult and expensive biomarker discovery method, this method uses the data pool of the library to perform discovery and validation together, saving time and cost and enabling a system that is easy to apply in the actual clinical environment.<Image>a. AUC to predict breast cancer b. Predicted Probability of 9 biomarkers for early diagnosis of breast cancer and deep learning algorithm(Normal, Stages 0-1, Stages 2-3, Other cancer (ovarian cancer, thyroid cancer, lung cancer, colon cancer and pancreatic cancer)The research team generated the library that is composed of 852 quantifiable peptides that cover 452 human blood proteins, and then selected and presented 9 proteins from them as biomarkers for breast cancer screening. The team also developed an algorithm for early screening of breast cancer using its deep learning technology specialized in simultaneous multiple analysis of proteins. The study was published in ‘Scientific Reports’ on June 2nd.Sungsoo Kim, Head of Bio Manufacturing subdivision, who led the research said, “These findings hold significance in that they show improved performance over MASTOCHECK®, which is currently commercially available, in screening for breast cancer. They also present an analysis platform that can be applied not only to breast cancer but also to various other diseases through the library.” He added, "Based on the results, Bertis will spare no efforts in future research and development to provide improved diagnostic tests to the medical field."Seung-man Han, CEO of Bertis, said, “This study has established an efficient biomarker discovery and validation system for the development of proteomics-based simultaneous multiple testing based on quantifiable proteins library and AI technology. Therefore, we expect that the introduction of innovative tests into the medical field will gain momentum.”Bertis is devoting itself to discovering biomarkers for major diseases and developing clinical solutions by incorporating proteomics technology accumulated over 10 years with the latest bioinformatics and AI technologies. The company has succeeded in commercializing proteomics technology through MASTOCHECK®, the world's first proteomics-based blood test solution for early breast cancer diagnosis, and PASS (Pan-omics Analysis Service & Solution), a pan-omics integrated analysis solution. It is also spurring its R&D efforts for early diagnosis solutions for various cancers, including pancreatic cancer and ovarian cancer, and analysis of blood proteomics with age.
- 게시물이 없습니다. wr_datetime desc